Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

REPROBESITY

Financiado

Cerrado

Search for new therapeutic agents against complicated obesity by reprofiling exi...

Search for new therapeutic agents against complicated obesity by reprofiling existing drugs Obesity is one of the most serious and fast-growing health problem in the European Union, and a leading cause of diabetes. The main barrier for approval of an anti-obesity drug is the safety requirements. We propose to overcome th... ver más

31/05/2012

FUNDACIÓN INSTITUT...

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

FUNDACIÓN INSTITUTO MEDITERRÁNEO PARA EL AVAN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 6M€

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2012-05-31 No tenemos la información de la convocatoria

0% 78% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

FUNDACIÓN INSTITUTO MEDITERR...

0.00€ | Lider

UNIBO

N.D. | Participante

UMC-Mainz

N.D. | Participante

Proyectos interesantes

ADAPT

Medical Technol...

Data Science

4M€ Cerrado

PTQ-09-02-02084

Medical Technol...

Pharmaceutical...

46K€ Cerrado

DESARROLLO DE MOLECULAS CON ACTIVIDAD TERAPEU...

Medical Technol...

Data Science

985K€ Cerrado

PID2021-126888OA-I00

Medical Technol...

Data Science

194K€ Cerrado

TOBI

Medical Technol...

Data Science

4M€ Cerrado

ADIBET

Medical Technol...

Data Science

1M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

FUNDACIÓN INSTITUTO MEDITERRÁNEO PARA EL AVAN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 6M€

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Obesity is one of the most serious and fast-growing health problem in the European Union, and a leading cause of diabetes. The main barrier for approval of an anti-obesity drug is the safety requirements. We propose to overcome this barrier by discovering phenotypes and biomarkers that identify subsets of patients with safe and efficacious responses to drugs, and by identifying new indications of existing drugs with proven safety profiles. To be approved, anti-obesity drugs need to show a decrease in abdominal fat. We focus on approaches targeting directly abdominal fat cells. In the last years only the cannabinoid CB1 receptor antagonist Rimonabant has been approved as a therapeutic agent to combat complicated obesity. Research performed with this drug has clearly revealed a role for the endogenous cannabinoid system in controlling energy homeostasis. However, its utility is limited to a restricted set of patients. A new phenotype and/or biomarker may identify responsive patients with good safety profiles. This proposal aims to discover novel or improved treatments in the shortest possible timeframe through three synergistic Specific Aims: 1) Clinical phenotyping of obese patients to identify those that would benefit from existing therapies such as Rimonabant. 2) Discover biomarkers for subsets of obese patients that may correlate with therapeutical outcomes. These biomarkers will be discovered by a novel approach called Combinatorial Cytomic Biomarkers developed by OrphaMed, applied to cells from two physiologically interlinked sources: blood and abdominal-fat samples, extracted from the above phenotyped patients. 3) Identify new indications of existing drugs, alone or in combination, with potential anti-obesity efficacy by lowering the fat content and the glucose uptake of abdominal fat cells, which would be expected to improve carbohydrate/lipid metabolism and lower body weight, extracted from the above phenotyped patients. This will be accomplished by screening approximately 2.000 known drugs against these fat cells using the novel technology platform ExviTech from OrphaMed. Candidates would be evaluated in animal models of obesity.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores